{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T08:56:46Z","timestamp":1780477006658,"version":"3.54.1"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T00:00:00Z","timestamp":1637884800000},"content-version":"am","delay-in-days":451,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.schres.2020.07.015","type":"journal-article","created":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T06:48:52Z","timestamp":1595659732000},"page":"373-375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Could the antipsychotic chlorpromazine be a potential treatment for SARS-CoV-2?"],"prefix":"10.1016","volume":"223","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2570-6996","authenticated-orcid":false,"given":"B.","family":"Nobile","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Courtet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Van de Perre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Nagot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Mol\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Oli\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.schres.2020.07.015_bb0005","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/13550280152537157","article-title":"A combination of low-dose chlorpromazine and neutralizing antibodies inhibits the spread of JC virus (JCV) in a tissue culture model: implications for prophylactic and therapeutic treatment of progressive multifocal leukencephalopathy","volume":"7","author":"Atwood","year":"2001","journal-title":"J. Neurovirol."},{"issue":"3","key":"10.1016\/j.schres.2020.07.015_bb0010","doi-asserted-by":"crossref","first-page":"e0194868","DOI":"10.1371\/journal.pone.0194868","article-title":"\u201cMERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells\u201d edited by S. P\u00f6hlmann","volume":"13","author":"Cong","year":"2018","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.schres.2020.07.015_bb0015","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.03036-14","article-title":"Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection","volume":"58","author":"Dyall","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"18","key":"10.1016\/j.schres.2020.07.015_bb0020","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1007\/s40265-017-0830-1","article-title":"Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies","volume":"77","author":"Dyall","year":"2017","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.schres.2020.07.015_bb0025","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/0006-2952(68)90180-9","article-title":"Distribution of chlorpromazine metabolites in selected organs of psychiatric patients chronically dosed up to the time of death","volume":"17","author":"Forrest","year":"1968","journal-title":"Biochem. Pharmacol."},{"issue":"16","key":"10.1016\/j.schres.2020.07.015_bb0030","doi-asserted-by":"crossref","first-page":"8722","DOI":"10.1128\/JVI.00253-07","article-title":"Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted","volume":"81","author":"Inoue","year":"2007","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.schres.2020.07.015_bb0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jgm.984","article-title":"Chlorpromazine and apigenin reduce adenovirus replication and decrease replication associated toxicity","volume":"9","author":"Kanerva","year":"2007","journal-title":"The Journal of Gene Medicine"},{"key":"10.1016\/j.schres.2020.07.015_bb0040","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.tips.2020.03.006","article-title":"Ongoing clinical trials for the management of the COVID-19 pandemic","volume":"41","author":"Lythgoe","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.schres.2020.07.015_bb0045","first-page":"207","article-title":"Chlorpromazine specifically inhibits peripheral and brain TNF production, and up-regulates IL-10 production, in mice","volume":"82","author":"Mengozzi","year":"1994","journal-title":"Immunology"},{"key":"10.1016\/j.schres.2020.07.015_bb0050","doi-asserted-by":"crossref","DOI":"10.1007\/s11481-020-09939-2","article-title":"Clomipramine could be useful in preventing neurological complications of SARS-CoV-2 infection","author":"Nobile","year":"2020","journal-title":"J. NeuroImmune Pharmacol."},{"issue":"1","key":"10.1016\/j.schres.2020.07.015_bb0055","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.schres.2020.07.015_bb0060","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.encep.2020.05.006","article-title":"Repositionnement de la chlorpromazine dans le traitement du COVID-19: \u00e9tude reCoVery","volume":"46","author":"Plaze","year":"2020","journal-title":"L\u2019Enc\u00e9phale"},{"issue":"8","key":"10.1016\/j.schres.2020.07.015_bb0065","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1128\/AAC.03011-14","article-title":"Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture","volume":"58","author":"de Wilde","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.schres.2020.07.015_bb0070","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jinf.2020.03.037","article-title":"The pathogenesis and treatment of the \u2018cytokine storm\u2019 in COVID-19","volume":"80","author":"Ye","year":"2020","journal-title":"J. Infect."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996420304011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996420304011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:40:42Z","timestamp":1760298042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996420304011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":14,"alternative-id":["S0920996420304011"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2020.07.015","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Could the antipsychotic chlorpromazine be a potential treatment for SARS-CoV-2?","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2020.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}